Our Take
This is sponsored content arguing for integration, but the cited research is real and independent—the actual risk is operational, not financial.
Why it matters
Health plans are tempted by carve-out vendors as drug costs climb. The data suggests that fragmentation creates coordination debt that eats savings elsewhere, a trap worth understanding before you split the model.
Do this week
Benefits leaders: audit your current PBM vendor for cross-system visibility on retail, specialty, and clinical claims before Q2 procurement decisions.
Two independent studies show integrated pharmacy wins on cost and hospitalizations
Research published in the Journal of Managed Care & Specialty Pharmacy examined specialty benefits integration across regional health plans and self-insured Blue plans. Results: plans using integrated models reported 3.7% lower medical costs and $8.73 lower spend per member per month (per the cited studies). The same integrated cohorts also reported fewer hospitalizations.
Blue Shield of California provides a cautionary counterpoint. After shifting to a modular pharmacy approach, the company disclosed in Modern Healthcare that it has not yet met its savings target. The company attributed the shortfall to vendor management complexity and the difficulty of negotiating direct deals across multiple partners.
Fragmentation trades cost savings for operational friction
The appeal of disaggregation is obvious: separate vendors, separate contracts, the promise of specialist efficiency. The hidden cost is visibility loss. When pharmacy claims, clinical programs, and member data live in disconnected systems, health plans lose the ability to identify cost drivers quickly, coordinate care across retail and specialty channels, or enforce compliance uniformly.
Blue Shield's experience suggests that savings gains promised by carve-out vendors assume flawless execution across multiple parties. When those parties don't share incentives or real-time data, the plan absorbs the coordination work—and often the cost. Administrative burden climbs. Negotiating leverage fragments. And the member experience splinters across touchpoints.
The research cited is independent and peer-reviewed, not a vendor benchmark, which makes it worth taking seriously. The 3.7% medical cost reduction is material for large plans. The hospitalization reduction signals clinical coordination gains that disaggregated models have not matched.
Map your current pharmacy ecosystem before committing to carve-out deals
If you are evaluating a disaggregated pharmacy strategy, do not rely on vendor promises alone. Audit your current claims flow: how many days does it take to identify a high-cost medication trend? How many systems does a care coordinator need to access to intervene on an at-risk member? What gaps exist in your cross-system visibility on rebates and formulary optimization?
Use those baselines to stress-test the vendor model. Ask each proposed partner how they will integrate with your other vendors, not just with your claims system. Require shared KPIs on cost reduction and clinical outcomes, tied to contract penalties. And study Blue Shield's case closely: the company had scale, PBM sophistication, and vendor relationships. If coordination costs still eroded savings there, they will likely do so elsewhere.